SCHEMBL4931441

SCHEMBL4931441

NC(=O)c1ccc(-c2nc(C(=O)O)c(NC(=O)c3c(Cl)cc(Cl)cc3Cl)s2)c(O)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 14/20 0.39
IKBKE Q14164 9/20 0.39
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP2C9 P11712 2/20 0.37
HPGD P15428 2/20 0.37
CYP2C19 P33261 2/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPC1 O15118 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
RECQL P46063 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PTPRC P08575 1/20 0.37
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4933915 0.81 TBK1 (0.41) TBK1IKBKEALDH1A1HPGD
SCHEMBL4931435 0.66 ANO1 (0.40) KDM4ENPC1RAB9APTPRC
SCHEMBL2832149 0.66 TBK1 (0.39) TBK1IKBKE
SCHEMBL29999252 0.65 HSD17B10 (0.54) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL5555769 0.64 KDM4E (0.51) TBK1IKBKEKDM4EALDH1A1CYP2C9
SCHEMBL30482350 0.63 TBK1 (0.48) TBK1IKBKEMAPT
SCHEMBL27041409 0.62 TTR (0.48) KDM4EALDH1A1GAASMN1; SMN2MAPT
SCHEMBL5431721 0.61 TBK1 (0.46) TBK1IKBKEKDM4E
SCHEMBL6503762 0.60 SHMT1 (0.56) KDM4EALDH1A1GAASMN1; SMN2NPC1
SCHEMBL4924406 0.60 HSPA5 (0.40) SMN1; SMN2NPC1MAPTRAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167309-A1 Pharmaceutical Compounds CCNO, CDK2, CDK1 TBK1 2327/4885IKBKE 89/4885KDM4E 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.